NASDAQ · ETON
Eton Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ETON: Nov 05, 2026
Eton Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0.34. The reported EPS for the same quarter last year was $-0.07.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.34 | $0.40 | $0.27 | 2 |
| Dec 2026 | $0.38 | $0.39 | $0.36 | 2 |
| Mar 2027 | $0.44 | $0.44 | $0.44 | 1 |
| Jun 2027 | $0.35 | $0.35 | $0.35 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool · BNK Invest- RTTNews · Oct 14, 8:15 AM EDTEton Licenses LIBERVANT For U.S. Seizure Rescue Market(RTTNews) – A cheek-administered seizure rescue therapy could soon provide patients and caregivers with another treatment option. Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) have entered into an exclusive U.S. licensing and supply agreement for LIBERVANT (dizaep
- Zacks · Oct 13, 9:47 AM EDTTGTX Stock Rises 60% in 6 Months: Here's What You Should KnowTG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
- Zacks · Oct 13, 9:41 AM EDTMirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesMIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
- Zacks · Oct 7, 11:08 AM EDTETON Stock Surges 108% in Six Months: Here's What You Need to KnowEton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
- RTTNews · Sep 28, 8:36 AM EDTEton Relaunches IMPAVIDO In U.S., Expands Patient Access Programs(RTTNews) – Eton Pharmaceuticals, Inc. (ETON) announced the U.S. commercial availability of IMPAVIDO (miltefosine) capsules, following the company's acquisition of exclusive U.S. commercialization rights to the product.
- The Motley Fool · Aug 20, 7:27 PM EDTEton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- BNK Invest · Aug 17, 8:51 AM EDTETON Crosses Above Average Analyst TargetIn recent trading, shares of Eton Pharmaceuticals Inc (Symbol: ETON) have crossed above the average analyst 12-month target price of $52.70, changing hands for $58.86/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrad
- RTTNews · Aug 17, 7:37 AM EDTBiotech Stocks At 52-Week Highs – ETON +44%, DXCM, ORKA, CON, ATAI(RTTNews) – The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition.
- RTTNews · Aug 17, 7:08 AM EDTEton Pharmaceuticals Swings To Q2 Profit; Revenue Jumps 99%(RTTNews) – Eton Pharmaceuticals, Inc. (ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, recently reported financial results for the second quarter ended June 30, 2026, with record revenue and strong earnings grow
- The Motley Fool · Aug 14, 2:58 PM EDTWhy Eton Pharmaceuticals Is Top of the Class TodayEton Pharmaceuticals beat on both top and bottom lines last night.
- MarketBeat · Aug 13, 8:03 PM EDTEton Pharmaceuticals Q2 Earnings Call HighlightsEton Pharmaceuticals (NASDAQ:ETON) reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook
- Zacks · Aug 13, 6:05 PM EDTEton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat EstimatesEton Pharmaceuticals (ETON) delivered earnings and revenue surprises of +218.18% and +38.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Eton Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.